Home Cart Sign in  
Chemical Structure| 118-34-3 Chemical Structure| 118-34-3

Structure of Syringin
CAS No.: 118-34-3

Chemical Structure| 118-34-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Syringin is a natural product isolated and purified from the fruits of Syringa vulgaris with antitumour,antiproliferative, anti-inflammatory and antinociceptive effects.

Synonyms: Eleutheroside B; NSC 287441; Lilacin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Syringin

CAS No. :118-34-3
Formula : C17H24O9
M.W : 372.37
SMILES Code : COC(C=C(C=C1OC)/C=C/CO)=C1O[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O
Synonyms :
Eleutheroside B; NSC 287441; Lilacin
MDL No. :MFCD00016778
InChI Key :QJVXKWHHAMZTBY-GCPOEHJPSA-N
Pubchem ID :5316860

Safety of Syringin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
N2a cells 1 mM 6 h To evaluate the protective effects of Syringin on N2a and APPswe cells under oxidative stress conditions. Results showed that Syringin pretreatment significantly reduced H2O2-induced ROS production and apoptosis, and improved cell cycle delay. PMC7452088
Rabbit atrial myocytes 200 μM Syringin significantly suppressed ATX II-induced Na+-dependent [Ca2+]i overload. PMC8026606
NSC-34 mouse motor neuron cells 0.25-8 μM 24 h Syringin improved PR-CM-induced motor neuron death and apoptosis PMC9563448
Rabbit atrial myocytes 300 μM Syringin significantly reduced ATX II-prolonged APD90 and eliminated ATX II-induced EADs, DADs, and TAs. PMC8026606
Rabbit atrial myocytes 167 μM Syringin concentration-dependently inhibited INaL, INaT, and ATX II-increased INaL with IC50 values of 167, 1582, and 181 μM, respectively. PMC8026606
MDA-MB-231 cells 0, 20, 40, 80, 160, and 320 µg/mL 24 h and 48 h Syringin significantly inhibited the proliferation of MDA-MB-231 cells with an IC50 of 228.8 µg/mL (48 h). PMC9258109
MCF-7 cells 0, 20, 40, 80, 160, and 320 µg/mL 24 h and 48 h Syringin significantly inhibited the proliferation of MCF-7 cells with an IC50 of 207.9 µg/mL (48 h). PMC9258109
SH-SY5Y cells 2-4 μM 24 h SRG pretreatment dose-dependently reduced 6-OHDA-induced cell death, with 4 μM SRG increasing cell survival rate by 1.6-fold PMC10527269

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
APP/PS1 transgenic mice and wild-type C57BL/6 mice Alzheimer's disease model Oral gavage 20 mg/kg and 60 mg/kg body weight Once daily for five months To evaluate the effects of Syringin on cognitive deficits and AD-related pathology in APP/PS1 mice. Results showed that Syringin treatment significantly improved cognitive function, reduced Aβ deposition, and enhanced synaptic plasticity in APP/PS1 mice. PMC7452088
New Zealand white rabbits Langendorff-perfused rabbit heart model Perfusion 200 μM 100 minutes EB substantially decreased ATX II-induced incidences of atrial fibrillation (AF), ventricular fibrillation (VF), and heart death. PMC8026606
Caenorhabditis elegans BZ555 (Pdat-1::GFP), NL5901 (Punc-54::α-Syn::YFP), DA2123 (lgg-1p::GFP::lgg-1), and VC199 (sir2.1 (ok434)) Culture medium treatment 1 mM Pretreatment for 24 hours, then exposed to 6-OHDA for 1 hour SRG pretreatment ameliorated 6-OHDA-induced degeneration of DA neurons, dopamine-mediated food-sensitive behavioral abnormalities, and shortened lifespan, and enhanced autophagic activity by upregulating the sir-2.1 pathway PMC10527269

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.69mL

0.54mL

0.27mL

13.43mL

2.69mL

1.34mL

26.86mL

5.37mL

2.69mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories